Here’s a wild fact: a coenzyme discovered in 1906 has become one of the hottest topics in aging research. NAD+ (nicotinamide adenine dinucleotide) sits in every cell of your body, quietly running hundreds of metabolic reactions. And it’s disappearing as you get older.
By middle age, NAD+ levels in many tissues have dropped by 50% or more. That decline cascades into broken DNA repair, struggling mitochondria, impaired gene regulation, and metabolic dysfunction. Researchers have spent the last decade asking: what if you could put it back?
The published science is substantial — and genuinely exciting. Here’s what the data shows.
This compound is supplied exclusively for in vitro and preclinical research. It is not intended for human consumption, therapeutic application, or diagnostic use.
NAD+ Has Two Jobs (And One Is Way More Interesting Than the Other)
Job 1: Energy production. NAD+ shuttles electrons through the metabolic machinery that turns food into ATP. It picks up electrons during glycolysis and the citric acid cycle (becoming NADH), then drops them off at the mitochondrial electron transport chain. Basic biochemistry, known for decades. Important, but not why NAD+ is making headlines.
Job 2: Cellular regulation. This is where it gets interesting. NAD+ isn’t just recycled in energy metabolism — it’s actually consumed by three families of enzymes that control DNA repair, gene expression, inflammation, and aging:
- Sirtuins (SIRT1-7): The “longevity genes.” NAD+-dependent enzymes that regulate DNA repair, mitochondrial health, inflammation, and gene expression. No NAD+ → no sirtuin activity → accelerated aging at the cellular level.
- PARPs: Your DNA repair crew. When DNA gets damaged, PARPs burn through NAD+ to fix it. More damage = more NAD+ consumed = less available for everything else.
- CD38: The villain of the story. This enzyme degrades NAD+ and its expression increases with age. More CD38 → faster NAD+ depletion → a vicious cycle.
Why NAD+ Drops With Age (And Who Found the Culprit)
In 2016, Camacho-Pereira and colleagues published a landmark paper in Cell Metabolism that pinpointed the primary driver of age-related NAD+ decline: CD38. This enzyme’s expression rises steadily with age across multiple tissues, progressively draining the NAD+ pool. It’s not that your body stops making NAD+ — it’s that something is chewing through it faster than it can be replaced.
The downstream effects cascade:
- Sirtuin activity drops → DNA repair and mitochondrial maintenance suffer
- PARP function gets compromised → DNA damage accumulates
- Mitochondria struggle → less energy, more reactive oxygen species
- Metabolic flexibility declines → cells can’t switch between fuel sources efficiently
It’s a domino effect that touches nearly every aspect of cellular aging.
How Cells Make NAD+ (Three Pathways)
The Salvage Pathway (the big one): Cells recycle nicotinamide — a byproduct of sirtuin and PARP activity — back into NAD+ through an enzyme called NAMPT. This is the dominant pathway in most tissues, and NAMPT is the bottleneck. Its expression declines with age in some tissues, compounding the problem.
The Preiss-Handler Pathway: Converts niacin (vitamin B3) into NAD+. Especially active in the liver.
The De Novo Pathway: Builds NAD+ from scratch using the amino acid tryptophan. A minor contributor in most tissues, but important in liver and kidney.
The Research That Got Everyone’s Attention
Reversing Mitochondrial Aging (Gomes et al., 2013)
This Cell paper was a bombshell. The team showed that NAD+ decline disrupts communication between the nucleus and mitochondria. Low NAD+ → low SIRT1 activity → HIF-1α stabilization → cells shift to glycolysis even when oxygen is plentiful (a “pseudohypoxic” state). The kicker: restoring NAD+ levels in aged mice reversed the mitochondrial dysfunction to levels resembling younger animals.
Better DNA Repair (Li et al., 2017)
Published in Science, this study showed that NAD+ repletion improved DNA repair in aged mouse cells and in cells from patients with XPA (a genetic DNA repair disorder). The mechanism ran through PARP1 activation and ATM kinase signaling — both NAD+-dependent. Essentially: give aging cells more NAD+, and they fix their own DNA better.
Blood Vessels That Act Young Again (Das et al., 2018)
Another Cell paper. NAD+ repletion in aged mice improved blood vessel function, grew new capillaries in skeletal muscle, and boosted exercise capacity. The pathway: SIRT1 activation in endothelial cells → hydrogen sulfide signaling → angiogenesis. Old mice with restored NAD+ had vascular function resembling much younger animals.
Brain Protection
The brain is especially vulnerable to NAD+ decline — it’s metabolically demanding and has limited regenerative capacity. Studies in neurodegenerative disease models have shown that NAD+ repletion improved neuronal survival, reduced neuroinflammation, and enhanced cognitive function in aged rodents.
NAD+ vs. NMN vs. NR: What’s the Difference?
Most popular discussion focuses on NAD+ precursors — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both feed into the salvage pathway and get converted to NAD+ inside cells. Key research considerations:
- Size matters: NAD+ (663 g/mol) is much larger than NMN (334) or NR (255), which may affect how cells absorb it
- Conversion required: Precursors need enzymes to become NAD+, and enzyme levels vary by tissue
- Transport: Recent research identified a specific NAD+ transporter (SLC12A8) in some tissues, suggesting direct uptake is possible
- Stability: Each form handles differently in solution and at various pH levels
Whether direct NAD+ or precursor supplementation produces better results remains an active research question — and likely depends on the tissue and context.
Product Specifications
- Molecular Weight: 663.43 g/mol
- Molecular Formula: C₂₁H₂₇N₇O₁₄P₂
- CAS Number: 53-84-9
- Physical Form: Sterile lyophilized powder
- Content: 500mg per vial (verified by independent testing)
- Purity: Verified by Janoshik Analytical
- Storage: -20°C for long-term, 2-8°C for short-term
Key References
- Camacho-Pereira J, et al. CD38 dictates age-related NAD decline. Cell Metab. 2016;23(6):1127-1139.
- Gomes AP, et al. Declining NAD+ induces a pseudohypoxic state. Cell. 2013;155(7):1624-1638.
- Li J, et al. A conserved NAD+ binding pocket that regulates protein-protein interactions during aging. Science. 2017;355:1312-1317.
- Das A, et al. Impairment of an endothelial NAD+-H₂S signaling network is a reversible cause of vascular aging. Cell. 2018;173(1):74-89.
- Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.
Browse NAD+ 500mg with verified COA from Janoshik Analytical. For related longevity research compounds, explore Epithalon and our full Longevity Research category.